✦ LIBER ✦

Thalidomide maintenance following high-dose therapy in multiple myeloma: a UK myeloma forum phase 2 study

✍ Scribed by Sylvia Feyler; Andy Rawstron; Graham Jackson; John A. Snowden; Kim Cocks; Roderick J. Johnson

Book ID: 108675440
Publisher: John Wiley and Sons
Year: 2007
Tongue: English
Weight: 123 KB
Volume: 139
Category: Article
ISSN: 0007-1048
DOI: 10.1111/j.1365-2141.2007.06817.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Long-term follow-up of idiotype vaccinat

Long-term follow-up of idiotype vaccination in human myeloma as a maintenance therapy after high-dose chemotherapy

✍ Coscia, M; Mariani, S; Battaglio, S; Di Bello, C; Fiore, F; Foglietta, M; Pileri 📂 Article 📅 2003 🏛 Nature Publishing Group 🌐 English ⚖ 200 KB

Low efficacy of thalidomide in improving

Low efficacy of thalidomide in improving response after induction in multiple myeloma patients who are candidates for high-dose therapy

✍ A. Corso; S. Mangiacavalli; L. Barbarano; L. Montalbetti; A. Mazzone; S. Fava; M 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 181 KB

Three courses of high dose therapy. Feas

Three courses of high dose therapy. Feasibility in the treatment of multiple myeloma–a “France autogreffe” study

✍ Philippe Colombat; Noel Milpied; Jean Philippe Laporte; Philippe Casassus; Claud 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 416 KB 👁 2 views

Pilot study of 13cis-retinoic acid+dexam

Pilot study of 13cis-retinoic acid+dexamethasone+alpha interferon as maintenance therapy following high-dose chemotherapy and autologous stem cell transplant for multiple myeloma

✍ Friedman, J; Khoury, H; Adkins, D; Devine, S; Nervi, B; Edwards, T; DiPersio, J; 📂 Article 📅 2005 🏛 Nature Publishing Group 🌐 English ⚖ 140 KB

Adenovector engineered interleukin-2 exp

Adenovector engineered interleukin-2 expressing autologous plasma cell vaccination after high-dose chemotherapy for multiple myeloma - a phase 1 study

✍ Trudel, S; Li, Z; Dodgson, C; Nanji, S; Wan, Y; Voralia, M; Hitt, M; Gauldie, J; 📂 Article 📅 2001 🏛 Nature Publishing Group 🌐 English ⚖ 305 KB

Phase 2 study of two sequential three-dr

Phase 2 study of two sequential three-drug combinations containing bortezomib, cyclophosphamide and dexamethasone, followed by bortezomib, thalidomide and dexamethasone as frontline therapy for multiple myeloma

✍ William I. Bensinger; Sundar Jagannath; Robert Vescio; Elber Camacho; Jeffrey Wo 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 155 KB